DK3191120T3 - Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt - Google Patents

Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt Download PDF

Info

Publication number
DK3191120T3
DK3191120T3 DK15767597.6T DK15767597T DK3191120T3 DK 3191120 T3 DK3191120 T3 DK 3191120T3 DK 15767597 T DK15767597 T DK 15767597T DK 3191120 T3 DK3191120 T3 DK 3191120T3
Authority
DK
Denmark
Prior art keywords
antagonists
progression
inhibit
patients
psoriatic arthritis
Prior art date
Application number
DK15767597.6T
Other languages
Danish (da)
English (en)
Inventor
Shephard Mpofu
Hanno Richards
Gregory Ligozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3191120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3191120T3 publication Critical patent/DK3191120T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
DK15767597.6T 2014-09-10 2015-09-08 Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt DK3191120T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
DK3191120T3 true DK3191120T3 (da) 2024-07-15

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15767597.6T DK3191120T3 (da) 2014-09-10 2015-09-08 Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt

Country Status (22)

Country Link
US (2) US11278618B2 (enExample)
EP (2) EP3191120B1 (enExample)
JP (4) JP2017528465A (enExample)
KR (3) KR20170045240A (enExample)
CN (4) CN107073110A (enExample)
AU (2) AU2015313827C1 (enExample)
BR (1) BR112017003332A2 (enExample)
CA (1) CA2960754A1 (enExample)
DK (1) DK3191120T3 (enExample)
ES (1) ES2981697T3 (enExample)
FI (1) FI3191120T3 (enExample)
HR (1) HRP20240921T1 (enExample)
HU (1) HUE067081T2 (enExample)
LT (1) LT3191120T (enExample)
MX (1) MX2017003216A (enExample)
PL (1) PL3191120T3 (enExample)
PT (1) PT3191120T (enExample)
RS (1) RS65851B1 (enExample)
RU (1) RU2697383C2 (enExample)
SI (1) SI3191120T1 (enExample)
SM (1) SMT202400285T1 (enExample)
WO (1) WO2016038538A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
US10676522B2 (en) * 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
EP3672988A1 (en) * 2017-08-23 2020-07-01 Eli Lilly and Company Treatment of genital psoriasis
AU2018361975A1 (en) * 2017-11-02 2020-05-07 Novartis Ag Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
US20200385453A1 (en) * 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
KR102604172B1 (ko) 2019-12-05 2023-11-22 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 베체트병 또는 류마티스 관절염 예방 또는 치료용 약학조성물
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
BRPI0813262A2 (pt) 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
MX356279B (es) * 2010-10-08 2018-05-22 Novartis Ag Star Métodos para el tratamiento de soriasis usando antagonistas de il-17.
AU2011325134B2 (en) * 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
TW201307845A (zh) * 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
RU2014125071A (ru) * 2011-11-21 2015-12-27 Новартис Аг Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla

Also Published As

Publication number Publication date
RU2017107501A3 (enExample) 2019-03-12
AU2015313827C1 (en) 2018-08-30
EP3191120B1 (en) 2024-04-10
SI3191120T1 (sl) 2024-10-30
EP4406969A3 (en) 2024-11-27
US20170281762A1 (en) 2017-10-05
RU2697383C2 (ru) 2019-08-13
FI3191120T3 (fi) 2024-07-10
AU2015313827A1 (en) 2017-02-16
JP7288927B2 (ja) 2023-06-08
JP2025024104A (ja) 2025-02-19
EP4406969A2 (en) 2024-07-31
CN113069542A (zh) 2021-07-06
RU2017107501A (ru) 2018-10-10
CN107073110A (zh) 2017-08-18
PT3191120T (pt) 2024-07-16
CN115944734A (zh) 2023-04-11
US11278618B2 (en) 2022-03-22
AU2015313827B2 (en) 2018-02-15
LT3191120T (lt) 2024-07-25
US20220313818A1 (en) 2022-10-06
KR20230170796A (ko) 2023-12-19
JP2023109973A (ja) 2023-08-08
HRP20240921T1 (hr) 2024-10-11
CN115957326A (zh) 2023-04-14
RS65851B1 (sr) 2024-09-30
ES2981697T3 (es) 2024-10-10
SMT202400285T1 (it) 2024-09-16
PL3191120T3 (pl) 2024-08-26
JP2021152021A (ja) 2021-09-30
JP7591092B2 (ja) 2024-11-27
AU2018201410A1 (en) 2018-03-22
CA2960754A1 (en) 2016-03-17
KR20260087713A (ko) 2026-06-11
WO2016038538A1 (en) 2016-03-17
KR20170045240A (ko) 2017-04-26
HUE067081T2 (hu) 2024-09-28
MX2017003216A (es) 2017-05-23
BR112017003332A2 (pt) 2017-11-28
EP3191120A1 (en) 2017-07-19
JP2017528465A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
NL301361I2 (nl) olezarsen of farmaceutisch aanvaardbare zouten daarvan
NO2022046I1 (no) Berotralstat and pharmaceutically acceptable salts thereof
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
DK3309924T3 (da) Terminal med to ladekredsløb
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
SI3221363T1 (sl) Protitelesa proti CD73 in njihova uporaba
DK3119464T3 (da) Intermitterende katetere med hydrerings-/gribeanordninger
DK3034453T3 (da) Udstyr med sideskifter
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
SI2968269T1 (sl) Postopek priprave antagonistov beta 3 in vmesnih spojin
HRP20181670T1 (hr) Spojevi pirazola i njihova uporaba kao blokatora kalcijevih kanala t-tipa
SI3191120T1 (sl) Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom
FR3030668B1 (fr) Joint filete
EP3390626A4 (en) LIQUID FORMULATION OF ALPHA AMYLASE
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
DK3266951T3 (da) Kompositkomponent med flade betonfærdigdele
DK2931393T3 (da) Vandforlystelsesbane med flydelegemer
DK3169723T3 (da) VOC-fri bearbejdningshjælpemiddel til anvendelse ved fremstilling af skum under anvendelse af blæsemidler med lavt potentielt bidrag til global opvarmning
DK3140050T3 (da) Dosering med visning
DK2944309T3 (da) Anvendelse af palmitoylethanolamid i kombination med opioider